New China Life Insurance (1336) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of New China Life Insurance HK$94.64, price HK$46.20, upside +104.9%, quality 66 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch New China Life Insurance for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range HK$10.11 – HK$65.15 · fair‑value band HK$70.98 – HK$118.30 · the HK$46.20 price screens below the HK$94.64 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow New China Life Insurance in your weekly email
Every Wednesday you see whether New China Life Insurance is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
New China Life Insurance Company Ltd. provides life insurance products and services to individuals and institutions in China. The company operates through three segments: Traditional insurance, Participating insurance, and Other Business. It provides life insurance, health insurance, and accident insurance products and services.
Show more
New China Life Insurance Company Ltd. provides life insurance products and services to individuals and institutions in China. The company operates through three segments: Traditional insurance, Participating insurance, and Other Business. It provides life insurance, health insurance, and accident insurance products and services. The company also offers asset management, investment management, training, electronic commerce, and medical services; elderly care services and enterprise management service; property management; and invests in, develops, leases, and manages real estate properties. The company was incorporated in 1996 and is headquartered in Beijing, China.
Stock analysis
New China Life Insurance (1336) currently trades at HK$46.20, while our model-based Fair Value estimate is HK$94.64, implying the stock looks roughly 51.2% undervalued today.
Show more
Valuation
Bull case: the Economic Profit group reads highest at a median of HK$110.10 per share, and 3 of the 4 models we run sit above the HK$46.20 price.
Bear case: the Asset-Based group reads lowest at HK$23.97, and 1 of the 4 models stay below the price. Evidence for this calculation is high.
Scenario range: HK$70.98 (bear) to HK$118.30 (bull), the price of HK$46.20 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Financial Services sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
New China Life Insurance reported revenue of 131B CNY in FY2025 versus 222B CNY in FY2021, a compound −12.4%/yr. Reported net income was 35.3B CNY in FY2025, compounding +24.0%/yr from FY2021.
Key figures
Market cap HK$144B (≈ $18.4B) · P/E ratio 3.5 · P/S ratio 0.94 · EPS (TTM) HK$8.64 · Dividend yield 6.3% · Net margin 27.0% · Return on equity 36.3% · Return on assets (EBIT) 1.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 29% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Financial Services peers we cover trades at −35% fair-value upside, at 105%, 1336 screens cheaper than that median.
Fair Value models
Bear HK$70.98Fair Value HK$94.64Bull HK$118.30
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$4.20 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+1.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.7%
Start year 2020 (pandemic). Over 10 years: −1.9% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+26.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+19.9%
Dividend (yield on the price)6.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.19% vs 19%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 30%
2025 sits 64% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Compare New China Life Insurance with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Insurance - Life · 95 stocks
Beats the industry median on 13/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score65 · Top 25%
Fair Value upside+102% · Top 25%
Profitability
Return on equity (TTM)36% · Top 25%
Return on assets1% · Above median
Net margin (TTM)49% · Top 25%
Operating margin (TTM)50% · Top 25%
Growth and dividend
Revenue growth3% · Below median
Dividend yield (TTM)6.3% · Top 25%
Balance sheet
Debt / equity0.18× · Below median
Valuation Multiplesvs Insurance - Life median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "New China Life Insurance Fair Value". https://www.fairvalue-calculator.com/stock/1336
Frequently asked questions
Is New China Life Insurance (1336) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of HK$94.64 versus a price of HK$46.20, about +105% upside (undervalued).
What is the fair value of 1336?
Our model-based fair value for New China Life Insurance is HK$94.64 (as of Sep 24, 2026), built from audited fundamentals. The current price: HK$46.20.
What is the quality score of 1336?
New China Life Insurance has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for New China Life Insurance (1336)?
Our model-based price target is the fair value of HK$94.64 (as of Sep 24, 2026) from 4 valuation models. Cautious scenario HK$70.98, optimistic scenario HK$118.30. It is a calculation from audited fundamentals, not an analyst target.
What is the New China Life Insurance stock forecast for 2026?
Our models put fair value at HK$94.64, about +105% upside versus a price of HK$46.20 (undervalued). Cautious scenario HK$70.98, optimistic scenario HK$118.30. The calculation is refreshed regularly with new filings.
What is the revenue of New China Life Insurance (1336)?
New China Life Insurance reported trailing-twelve-month revenue of about 75.1B CNY (latest available figure, as of Sep 24, 2026).
Does New China Life Insurance pay a dividend?
New China Life Insurance currently shows a dividend yield of about 6.31% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of New China Life Insurance (1336)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For New China Life Insurance it is HK$94.64 per share (as of Sep 24, 2026), against a price of HK$46.20. It is the blended result of 4 valuation models (cash flow, earnings, asset, dividend).
Is New China Life Insurance stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 1336 trades below its calculated fair value: price HK$46.20, fair value HK$94.64, a gap of about +105% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1336?
No. The price is what the market pays today (HK$46.20); the fair value is what the company's own numbers justify (HK$94.64). For New China Life Insurance the two are HK$48.44 per share apart. That gap is exactly why we show both numbers side by side.
How much is New China Life Insurance worth?
The market values New China Life Insurance at about HK$144B (market capitalisation, as of Sep 24, 2026). Per share that is HK$46.20; our models calculate a fair value of HK$94.64 per share.
What do the bullish and bearish scenarios say about 1336?
Our models span a range for New China Life Insurance: cautious scenario HK$70.98, base HK$94.64, optimistic HK$118.30 per share (as of Sep 24, 2026, price HK$46.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1336?
New China Life Insurance trades at a price-to-earnings ratio of 3.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$94.64 is built from several models across several years. Other multiples: PEG 0.4, P/B 1.1, P/S 1.7, EV/EBITDA 2.4.
What is the PEG ratio of 1336?
The PEG ratio of New China Life Insurance is 0.39 (P/E divided by earnings growth, as of Sep 24, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of New China Life Insurance (1336)?
Balance-sheet figures for New China Life Insurance (as of Sep 24, 2026): return on equity 36.3%, debt of 0.18 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is 1336 from its 52-week high?
New China Life Insurance trades at HK$46.20, about 29% below its 52-week high of HK$65.15 and 11% above the low of HK$41.53 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of HK$94.64 is for.
Which stocks are comparable to New China Life Insurance?
From the same area (Financial Services) we also value China Life Insurance Company, Ping An Insurance (Group) Company, AIA Group, Manulife Financial Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is New China Life Insurance stock attractive at the current price?
The data as of Sep 24, 2026: price HK$46.20, calculated fair value HK$94.64 (+105%), Quality Score 66/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1336 calculated?
We run New China Life Insurance through 4 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$94.64, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. New China Life Insurance currently trades 105 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of New China Life Insurance (1336)?
The closing price on Sep 24, 2026 was HK$46.20. Our model-based fair value is HK$94.64, about +105% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with New China Life Insurance right now?
The price is below even our cautious bear case (HK$70.98). The market is more pessimistic than our downside scenario. Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality. For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Where does the earnings growth of New China Life Insurance (1336) come from?
Earnings per share at New China Life Insurance grew +15.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share −3.3 %, EBIT margin +16.0 %, tax rate +2.6 %, residual (interest, one-offs) +0.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of New China Life Insurance
How large is the market capitalisation of New China Life Insurance (1336)?
The market capitalisation of New China Life Insurance is HK$144B (≈ $18.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of New China Life Insurance (1336)?
The price-to-sales ratio of New China Life Insurance is 0.94 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of New China Life Insurance (1336)?
Earnings per share at New China Life Insurance are HK$8.64 (price ÷ EPS = P/E 3.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of New China Life Insurance (1336)?
The dividend yield of New China Life Insurance is 6.3% (payout 33.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of New China Life Insurance (1336)?
The net margin of New China Life Insurance is 27.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of New China Life Insurance (1336)?
The return on equity (ROE) of New China Life Insurance is 36.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of New China Life Insurance (1336)?
On an EBIT basis the return on assets of New China Life Insurance is 1.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of New China Life Insurance (1336)?
The operating margin of New China Life Insurance is 50.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at New China Life Insurance (1336)?
Revenue at New China Life Insurance is growing +3.2% versus a year earlier (3y avg +7.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at New China Life Insurance (1336)?
Earnings per share at New China Life Insurance are growing +10.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does New China Life Insurance (1336) generate?
The free cash flow of New China Life Insurance is 153B CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does New China Life Insurance (1336) carry?
The net debt of New China Life Insurance is 170B CNY (fiscal year 2025, ≈ 1.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch New China Life Insurance in the live analysis
One click puts New China Life Insurance on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
